REaCT-VA HER2 positive
| REaCT-VA HER2 positive |
Central line access (PICC vs PORT) for breast cancer patients receiving adjuvant chemotherapy plus Herceptin Principal Investigator(s): Dr. Mark Clemons |
| ClinicalTrials.gov: NCT02632435 | |
| Intravenous trastuzumab is a common treatment regime for patients with early stage breast cancer. Adjuvant breast cancer chemotherapy require repeated visits to the chemotherapy unit and blood testing, along with trastuzumab treatment for 1 year. Thus vascular access devices are required to assist in efficient and effective treatment delivery and to improve patient experience. The best practice of type of vascular access is currently unknown (PICC vs. PORT). This study is complete. | |
|
Sites: The Ottawa Hospital |
|
|
Publications: Systematic Review:
|
|